Nasopharyngeal Cancer - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 87 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nasopharyngeal Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Nasopharyngeal Cancer - Pipeline Review, H1 2015', provides an overview of the Nasopharyngeal Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nasopharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Nasopharyngeal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Nasopharyngeal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Nasopharyngeal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Nasopharyngeal Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Nasopharyngeal Cancer - Overview 10
Pipeline Products for Nasopharyngeal Cancer - Comparative Analysis 11
Nasopharyngeal Cancer - Therapeutics under Development by Companies 12
Nasopharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes 14
Nasopharyngeal Cancer - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Nasopharyngeal Cancer - Products under Development by Companies 18
Nasopharyngeal Cancer - Products under Investigation by Universities/Institutes 19
Nasopharyngeal Cancer - Companies Involved in Therapeutics Development 20
Ambrx, Inc. 20
AVEO Pharmaceuticals, Inc. 21
BioDiem Ltd 22
Celgene Corporation 23
Cyclacel Pharmaceuticals, Inc. 24
F. Hoffmann-La Roche Ltd. 25
GlaxoSmithKline plc 26
Merck & Co., Inc. 27
Otsuka Holdings Co., Ltd. 28
Pharmacyclics, Inc. 29
Theravectys S.A. 30
Zhejiang BetaPharma Co., Ltd. 31
Nasopharyngeal Cancer - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
abexinostat hydrochloride - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
azacitidine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Cell Therapy for Metastatic Nasopharyngeal Carcinoma and Colorectal Cancer - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Cell Therapy for Nasopharingeal Carcinoma - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Cell Therapy to Target Latent Membrane Protein-2 for Oncology - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Cell Therapy to Target LMP-1 and LMP-2 for Metastatic Nasopharyngeal Carcinoma - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Cell Therapy to Target LMP-1 and LMP-2 for Oncology - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Dendritic Cells + Cytokine Induced Killer Cells - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
EBV-nRNA - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ficlatuzumab - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Gene Therapy to Activate p53 for Oncology - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
GSK-2849330 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
icotinib hydrochloride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MK-2206 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Monoclonal Antibody Drug Conjugate to Inhibit CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
NEO-212 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
OPB-51602 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
RO-5203280 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
seliciclib - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecules for Nasopharyngeal and Colon Cancers - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Stem Cell Therapy for Oncology - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Vaccine for EBV Associated Nasopharyngeal Cancer - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Vaccine for Epstein-Barr Viral Infections and Nasopharyngeal Cancer - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Vaccine to Target EBV for Nasopharyngeal Carcinoma - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Nasopharyngeal Cancer - Recent Pipeline Updates 75
Nasopharyngeal Cancer - Dormant Projects 80
Nasopharyngeal Cancer - Product Development Milestones 81
Featured News & Press Releases 81
Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer 81
May 29, 2009: Cyclacel Reports Initial Phase 2 Seliciclib Data In Patients With Nasopharyngeal Carcinoma At 2009 Asco Annual Meeting 82
Apr 21, 2009: Cyclacel & Dartmouth Researchers Reports Novel Mechanism Of Action For Seliciclib At AACR 82
Mar 05, 2009: Cyclacel Announces Phase 1 Data Elucidating Pharmacodynamics & Mechanism Of Action Of Seliciclib In Nasopharyngeal Cancer 83
Aug 28, 2008: CYCLACEL Announces Recommendations Of Data Review Committee For Seliciclib Phase 2b Non-Small Cell Lung Cancer APPRAISE Trial 84
Jun 28, 2007: Cyclacel Pharmaceuticals Announces Results Of Phase II Seliciclib Combination Studies 84
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87

List of Tables
Number of Products under Development for Nasopharyngeal Cancer, H1 2015 10
Number of Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Investigation by Universities/Institutes, H1 2015 19
Nasopharyngeal Cancer - Pipeline by Ambrx, Inc., H1 2015 20
Nasopharyngeal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 21
Nasopharyngeal Cancer - Pipeline by BioDiem Ltd, H1 2015 22
Nasopharyngeal Cancer - Pipeline by Celgene Corporation, H1 2015 23
Nasopharyngeal Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015 24
Nasopharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 25
Nasopharyngeal Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 26
Nasopharyngeal Cancer - Pipeline by Merck & Co., Inc., H1 2015 27
Nasopharyngeal Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 28
Nasopharyngeal Cancer - Pipeline by Pharmacyclics, Inc., H1 2015 29
Nasopharyngeal Cancer - Pipeline by Theravectys S.A., H1 2015 30
Nasopharyngeal Cancer - Pipeline by Zhejiang BetaPharma Co., Ltd., H1 2015 31
Assessment by Monotherapy Products, H1 2015 32
Assessment by Combination Products, H1 2015 33
Number of Products by Stage and Target, H1 2015 35
Number of Products by Stage and Mechanism of Action, H1 2015 37
Number of Products by Stage and Route of Administration, H1 2015 39
Number of Products by Stage and Molecule Type, H1 2015 41
Nasopharyngeal Cancer Therapeutics - Recent Pipeline Updates, H1 2015 75
Nasopharyngeal Cancer - Dormant Projects, H1 2015 80